Citation Impact
Citing Papers
Interleukin-1 in the pathogenesis and treatment of inflammatory diseases
2011 Standout
Immunomodulatory Function of Interleukin 28B During Primary Infection With Cytomegalovirus
2014 StandoutNobel
Intracellular Nucleic Acid Sensors and Autoimmunity
2011 StandoutNobel
The effect of CTLA-4 A49G polymorphism on rheumatoid arthritis risk: a meta-analysis
2014
From stress to inflammation and major depressive disorder: A social signal transduction theory of depression.
2014 Standout
Inflammation and Its Discontents: The Role of Cytokines in the Pathophysiology of Major Depression
2009 Standout
Validation of TaqMan® SNP genotyping specificity for rs12979860 of IL-28B: Modeling primer specificity in vitro
2014
The Second Canadian Symposium on Hepatitis C Virus: A Call to Action
2013 StandoutNobel
NF-κB signaling in inflammation
2017 Standout
Recapitulation of the hepatitis C virus life-cycle in engineered murine cell lines
2013 StandoutNobel
Mechanisms of hepatic stellate cell activation
2017 Standout
Predictors of viral kinetics to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b
2007
Hepatitis C treatment access and uptake for people who inject drugs: a review mapping the role of social factors
2013
Combined effects of different interleukin-28B gene variants on the outcome of dual combination therapy in chronic hepatitis C virus type 1 infection
2012
Recommendations for the Management of Hepatitis C Virus Infection Among People Who Inject Drugs
2013
Diagnosis, management, and treatment of hepatitis C: An update # † ‡
2008 Standout
Molecular Mechanisms of Depression: Perspectives on New Treatment Strategies
2013 Standout
Incidence and Preventability of Adverse Drug Events Among Older Persons in the Ambulatory Setting
2003 Standout
The evolutionary significance of depression in Pathogen Host Defense (PATHOS-D)
2012
Cryoglobulinemia and renal disease
2008
Peginterferon Alfa-2a and Ribavirin in Latino and Non-Latino Whites with Hepatitis C
2009
Interferon-based hepatitis C treatment in patients with pre-existing severe mental illness and substance use disorders
2009
The Impact of eHealth on the Quality and Safety of Health Care: A Systematic Overview
2011 Standout
Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance
2009 StandoutNature
Genes and hepatitis C: susceptibility, fibrosis progression and response to treatment
2011
IL-28B is a Key Regulator of B- and T-Cell Vaccine Responses against Influenza
2014 StandoutNobel
Functional polymorphisms in the interleukin-6 and serotonin transporter genes, and depression and fatigue induced by interferon-α and ribavirin treatment
2008
The Proportion of Regulatory T Cells in Patients with Rheumatoid Arthritis: A Meta-Analysis
2016 StandoutNobel
Management of HCV and HIV infections among people who inject drugs
2011
Definition of rapid virologic response with a highly sensitive real-time PCR-based HCV RNA assay in peginterferon alfa-2a plus ribavirin response-guided therapy
2010
The HCV Life Cycle: In vitro Tissue Culture Systems and Therapeutic Targets
2014 Standout
A review on the oxidative and nitrosative stress (O&NS) pathways in major depression and their possible contribution to the (neuro)degenerative processes in that illness
2010 Standout
Differential Diagnosis of Glomerular Disease: A Systematic and Inclusive Approach
2013 Standout
Optimal therapy in genotype 1 patients
2009
Improving clinical practice using clinical decision support systems: a systematic review of trials to identify features critical to success
2005 Standout
Boceprevir for Untreated Chronic HCV Genotype 1 Infection
2011 Standout
Can we vaccinate against depression?
2012
+49A/G polymorphism of cytotoxic T‐lymphocyte antigen 4 gene in type 1 autoimmune hepatitis and primary biliary cirrhosis: A meta‐analysis
2011
The role of inflammation in depression: from evolutionary imperative to modern treatment target
2015 Standout
Replication of hepatitis C virus
2007 StandoutNobel
Peginterferon alfa and ribavirin for chronic hepatitis C in patients eligible for shortened treatment, re-treatment or in HCV/HIV co-infection: a systematic review and economic evaluation
2011
Effects of computerized physician order entry and clinical decision support systems on medication safety: a systematic review.
2003 Standout
Polymorphisms in melanoma differentiation‐associated gene 5 link protein function to clearance of hepatitis C virus
2014 StandoutNobel
Pathogen Recognition and Inflammatory Signaling in Innate Immune Defenses
2009 Standout
The impact of the interferon-lambda family on the innate and adaptive immune response to viral infections
2014 StandoutNobel
Internal Initiation Stimulates Production of p8 Minicore, a Member of a Newly Discovered Family of Hepatitis C Virus Core Protein Isoforms
2009 StandoutNobel
The HCV IRES pseudoknot positions the initiation codon on the 40S ribosomal subunit
2010 StandoutNobel
Antisense Gets a Grip on miR-122 in Chimpanzees
2010 StandoutNobel
Computerized advice on drug dosage to improve prescribing practice
2008
Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care
2011 Standout
Response of Hepatitis C Virus to Long-Term Passage in the Presence of Alpha Interferon: Multiple Mutations and a Common Phenotype
2013 StandoutNobel
Selective activation of Toll-like receptor 7 in activated hepatic stellate cells may modulate their profibrogenic phenotype
2012
EASL Recommendations on Treatment of Hepatitis C 2018
2018 Standout
Inflammatory responses and inflammation-associated diseases in organs
2017 Standout
Innate immunity in alcoholic liver disease
2011
Silymarin/Silybin and Chronic Liver Disease: A Marriage of Many Years
2017 Standout
Cutting Edge: Chronic Inflammatory Liver Disease in Mice Expressing a CD28-Specific Ligand
2012 StandoutNobel
Investigation of TLR5 and TLR7 as candidate genes for susceptibility to systemic lupus erythematosus.
2009
Antiretroviral Use in the CEASE Cohort Study and Implications for Direct-Acting Antiviral Therapy in Human Immunodeficiency Virus/Hepatitis C Virus Coinfection
2016 StandoutNobel
The 3rd Canadian Symposium on Hepatitis C Virus: Expanding Care in the Interferon-Free Era
2014 StandoutNobel
Guidelines for the management of hemophilia
2012 Standout
Therapeutic Targeting of Toll-Like Receptors for Infectious and Inflammatory Diseases and Cancer
2009
Works of V Weich being referenced
Importance of Minimal Residual Viremia for Relapse Prediction in Patients With Chronic Hepatitis C Genotype 1 Infection
2011
GNB3 C825T polymorphism and response to interferon-alfa/ribavirin treatment in patients with hepatitis C virus genotype 1 (HCV-1) infection
2005
Gender-dependent association of CTLA4 polymorphisms with resolution of hepatitis C virus infection
2006
Hepatitis C treatment in “difficult-to-treat” psychiatric patients with pegylated interferon-alpha and ribavirin
2007
A Toll-like receptor 7 single nucleotide polymorphism protects from advanced inflammation and fibrosis in male patients with chronic HCV-infection
2007
Association of TLR7 single nucleotide polymorphisms with chronic HCV‐infection and response to interferon‐a‐based therapy
2007
Association of CTLA4 single nucleotide polymorphisms with viral but not autoimmune liver disease
2007
Individualized treatment strategy according to early viral kinetics in hepatitis C virus type 1–infected patients†‡
2009
Evaluation of complement factor 5 variants as genetic risk factors for the development of advanced fibrosis in chronic hepatitis C infection
2008
Low-density lipoprotein receptor variants are associated with spontaneous and treatment-induced recovery from hepatitis C virus infection
2009
559 Individualized treatment strategy with peginterferon alpha-2b (PEG-IFN a) plus ribavirin according to early viral kinetics in hepatitis C virus (HCV) type 1 infected patients
2006